Status:
TERMINATED
T Cells in Predicting Acute Graft-Versus-Host Disease in Patients Undergoing Donor Stem Cell Transplant
Lead Sponsor:
Vanderbilt-Ingram Cancer Center
Collaborating Sponsors:
National Cancer Institute (NCI)
National Institutes of Health (NIH)
Conditions:
Breast Cancer
Chronic Myeloproliferative Disorders
Eligibility:
All Genders
18-120 years
Brief Summary
RATIONALE: Studying samples of blood from patients with cancer in the laboratory may help doctors predict whether patients undergoing donor stem cell transplant will develop acute graft-versus-host di...
Detailed Description
OBJECTIVES: * To determine the association between regulatory T-lymphocyte (Treg) subsets present at engraftment and at day 28 with the incidence of acute graft-versus-host-disease (aGVHD) in patient...
Eligibility Criteria
Inclusion
- Inclusion criteria:
- Patients undergoing allogeneic SCT
- Age \>= 18 years
- Exclusion criteria:
- Inability to give informed consent
- Patients who have not received an allogeneic SCT
- Any condition which, in the opinion of the investigator, might interfere with study objective
- Any reason which, in the opinion of the investigator, adds additional risk to the patient
Exclusion
Key Trial Info
Start Date :
December 1 2006
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
October 1 2019
Estimated Enrollment :
150 Patients enrolled
Trial Details
Trial ID
NCT00651716
Start Date
December 1 2006
End Date
October 1 2019
Last Update
November 15 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Vanderbilt-Ingram Cancer Center
Nashville, Tennessee, United States, 37232-6838